Retatrutide’s filing target: what the milestone means
Lilly’s stated Q1 2027 US filing target is a development milestone. Here is how to distinguish a company plan from a regulatory decision.
Read the article →THE PEPTIDE NEWS ARCHIVE
Reporting, in context.
Research briefings and Canadian perspectives, with the sources close at hand.
Reading Health Canada’s peptide advisories beyond the label
Two dated regulator notices explain why research-use wording, product identity and regulatory authorisation need to be read separately.
Read the article →Vienna’s peptide symposium: what to follow this week
The European Peptide Symposium is underway. A guide to its research themes and the autumn meetings that follow.
Read the article →